Ray Dalio Seagen Inc. Transaction History

Bridgewater Associates, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$191.51 - $216.16 $189,211 - $213,566	988 New	988 $209,000
Q4 2022 Feb 13, 2023	BUY	$117.37 - $139.17 $963,607 - $1.14 Million	8,210 Added 478.16%	9,927 $1.28 Million
Q3 2022 Nov 10, 2022	SELL	$135.27 - $180.11 $1.45 Million - $1.93 Million	-10,742 Reduced 86.22%	1,717 $235,000
Q2 2022 Aug 11, 2022	BUY	$108.81 - $179.33 $273,330 - $450,476	2,512 Added 25.25%	12,459 $2.2 Million
Q1 2022 May 13, 2022	BUY	$119.61 - $157.85 $1.19 Million - $1.57 Million	9,947 New	9,947 $1.43 Million

Q4 2021 Feb 14, 2022	SELL	$142.57 - $190.86 $571,135 - $764,585	-4,006 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$142.45 - $169.82 $870,654 - $1.04 Million	-6,112 Reduced 60.41%	4,006 $680,000
Q2 2021 Aug 13, 2021	BUY	$135.08 - $161.1 $1.37 Million - $1.63 Million	10,118 New	10,118 $1.6 Million
Q1 2021 May 14, 2021	SELL	$137.51 - $190.8 $199,251 - $276,469	-1,449 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$164.63 - $211.93 $238,548 - $307,086	1,449 New	1,449 $254,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Bridgewater Associates, LP, based on Form 13F filings with the SEC.

Stay updated on Bridgewater Associates, LP and Ray Dalio with notifications on news.